Sona Nanotech Inc.
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of those who acquired Sona Nanotech Inc. (“SONA” or the “Company”) (OTCQB: SNANF) securities during the period from July 2, 2020 through November 25, 2020, inclusive (the “Class Period”). Investors have until February 16, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
According to the Complaint, the Company made false and misleading statements to the market. Sona unreasonably represented to the market that it could receive field studies of its COVID-19 antigen test within one month. The Company's positive statements about its antigen tests were unfounded. In fact, the FDA would deprioritize emergency use authorization approval of the Company's antigen test stating it did not meet "the public health need." The Company did not have a reasonable basis to believe that data collected in a short time would be acceptable to the FDA or Health Canada. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Sona, investors suffered damages.
If you purchased or otherwise acquired SONA securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at firstname.lastname@example.org, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.